期刊
CANCERS
卷 13, 期 15, 页码 -出版社
MDPI
DOI: 10.3390/cancers13153675
关键词
topoisomerase II; catalytic inhibitor; computer-aided drug design; cytotoxicity; DNA binding blocker
类别
资金
- Terry Fox New Frontier Program Project [1062]
- Prostate Cancer Foundation of BC
- NSERC-CREATE scholarship
DNA topoisomerase II (TOP2) is a drug target for many types of cancers. Clinically used TOP2 inhibitors can have serious side effects, but new inhibitors with different mechanisms of action are being developed to effectively control tumor growth. The compound T638, a catalytic TOP2 inhibitor, shows promising potential as an anticancer drug candidate with limited genotoxicity to cells.
Simple Summary DNA topoisomerase II (TOP2) is a drug target for many types of cancers. However, clinically used TOP2 inhibitors not only kill cancer cells, but also damage normal cells, and can even give rise to other types of cancers. To discover new TOP2 inhibitors to more effectively treat cancer patients, we have applied computer-aided drug design technology to develop several TOP2 inhibitors that can strongly inhibit cancer cell growth but exert low side effects. Results of one exemplary compound are presented in this study. It shows several promising drug-like properties that can be potentially developed into anticancer drugs. Clinically used topoisomerase II (TOP2) inhibitors are poison inhibitors that induce DNA damage to cause cancer cell death. However, they can also destroy benign cells and thereby show serious side effects, including cardiotoxicity and drug-induced secondary malignancy. New TOP2 inhibitors with a different mechanism of action (MOA), such as catalytic TOP2 inhibitors, are needed to more effectively control tumor growth. We have applied computer-aided drug design to develop a new group of small molecule inhibitors that are derivatives of our previously identified lead compound T60. Particularly, the compound T638 has shown improved solubility and microsomal stability. It is a catalytic TOP2 inhibitor that potently suppresses TOP2 activity. T638 has a novel MOA by which it binds TOP2 proteins and blocks TOP2-DNA interaction. T638 strongly inhibits cancer cell growth, but exhibits limited genotoxicity to cells. These results indicate that T638 is a promising drug candidate that warrants further development into clinically used anticancer drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据